Supported via arm's length funding from Bayer
Venous thromboembolism in cancer
Treatment options for VTE: the HOKUSAI VTE cancer trial
From LMWHs to DOACs: apixaban and rivaroxaban in clinical trials
Treating cancer associated-VTE with DOACs in clinical practice
Prevention: epidemiology of VTE in the cancer population
Stratifying patients with cancer according to risk of VTE
Screening of lower extremities for VTE risk assessment
Mortality in patients with cancer associated-VTE
CASSINI: Rivaroxaban demonstrates thromboprophylactic efficacy in high-risk ambulatory patients with cancer
BELIEVE: Luspatercept significantly reduces transfusion burden versus placebo in patients with beta-thalassaemia
TITAN and HERCULES: Caplacizumab - a new treatment option for patients with life-threatening aTTP?
MAIA: Daratumumab with lenalidomide plus dexamethasone for the treatment of transplant-ineligible, newly diagnosed multiple myeloma
Alliance: Ibrutinib demonstrates superior PFS to standard CIT in treatment-naive patients aged ≥65 with CLL
SPIRIT 2: 5-year data released from the largest (n=814) study of imatinib and dasatinib in newly diagnosed CML
Top image: © Racksuz
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
Supported by
